Bronchodilator therapy of COPD. A reanalysis suggests new roles and new concerns.
作者信息
Deffebach M E
出版信息
Chest. 1996 Jul;110(1):5-6. doi: 10.1378/chest.110.1.5.
PMID:8681663
Abstract
摘要
相似文献
1
Bronchodilator therapy of COPD. A reanalysis suggests new roles and new concerns.
Chest. 1996 Jul;110(1):5-6. doi: 10.1378/chest.110.1.5.
2
The clinical role of long-acting beta2-agonists in COPD.
Respir Med. 2000 Sep;94 Suppl E:S1-5. doi: 10.1016/s0954-6111(00)90154-9.
3
Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.
Chest. 1996 Jan;109(1):294. doi: 10.1378/chest.109.1.294.
4
Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD.
Chest. 1996 Jan;109(1):293. doi: 10.1378/chest.109.1.293-a.
5
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med. 2001 Apr;163(5):1087-92. doi: 10.1164/ajrccm.163.5.9903053.
6
Response to inhaled bronchodilators in COPD.
Chest. 1987 May;91(5 Suppl):36S-39S.
7
Bronchodilator therapy in chronic airflow obstruction.
Chest. 1984 Aug;86(2):161-2. doi: 10.1378/chest.86.2.161.
8
A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease.
Respir Med. 1996 Sep;90(8):497-9. doi: 10.1016/s0954-6111(96)90178-x.
9
Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Drugs Aging. 2001;18(6):441-72. doi: 10.2165/00002512-200118060-00006.
10
Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease.
Chest. 1990 Feb;97(2):280-4. doi: 10.1378/chest.97.2.280.
Zotero 插件